跳至主要内容
临床试验/NCT06174363
NCT06174363招募中不适用

Analgesic Efficacy of Maxigesic Added to Opioid Based-PCA in Patients Undergoing Breast Cancer Surgery

Yonsei University1 个研究点 分布在 1 个国家目标入组 84 人开始时间: 2023年12月28日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
入组人数
84
试验地点
1
主要终点
Analgesic effect of Maxigesic

研究概览

简要总结

The present study aims to find a perioperative analgesic method that provides sufficient analgesia while reducing immune compromise in cancer surgery. This study is to investigate the analgesic effect and safety of Maxigesic inj. (a combination of acetaminophen 1000 mg and ibuprofen 300 mg), which is added to opioid-based IV-PCA in patients undergoing breast cancer surgery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Triple (Participant, Care Provider, Outcomes Assessor)

入排标准

年龄范围
20 Years 至 70 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Patient aged 20 to 70 years with ASA classification 1 to 3 undergoing breast cancer surgery (cancer resection or reconstruction)

排除标准

  • ASA classification 4/ allergy to acetaminophen, NSAIDs, opioid/ severe liver or renal dysfunction/ pregnancy

研究组 & 干预措施

Study group

Placebo Comparator

Group administered Maxigesic solution

干预措施: Maxigesic (Drug)

Control group

Experimental

Group administerd 0.9% saline solution

干预措施: 0.9% saline solution (Drug)

结局指标

主要结局

Analgesic effect of Maxigesic

时间窗: postoperative 30 minutes/ 6 hours/ 24 hours/ 48 hours

Postoperative pain intensity is assessed with NRS: numerical rating scales (0 = no pain ∼ 10 = worst pain).

次要结局

  • Incidence of Adverse reactions (Safety)(postoperative 30 minutes/ 6 hours/ 24 hours/ 48 hours)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jin Sun Cho

M.D, PhD

Yonsei University

研究点 (1)

Loading locations...

相似试验